Delving into the Latest Updates on TR-987 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Glucoprime, GLYC-101, MG-3601

+ [3]

Target

TLR2

Action

modulators, stimulants

Mechanism

TLR2 modulators(Toll like receptor 2 modulators), Macrophages stimulants

Therapeutic Areas

Cardiovascular DiseasesSkin and Musculoskeletal DiseasesOther Diseases

Active Indication

Chronic venous insufficiencyVaricose UlcerWounds and Injuries

Inactive Indication-

Originator Organization

Kazia Therapeutics Ltd.

Active Organization

TR Therapeutics, Inc.

Kazia Therapeutics Ltd.

Inactive Organization

Glycotex, Inc.

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

The primary objectives of this study are to evaluate safety and efficacy of topically applied Glucoprime gel (GLYC-101, 0.1% and GLYC-101, 1.0%) in promoting wound healing in cosmetic surgery patients undergoing Carbon Dioxide Laser Skin Resurfacing (CO2 LSR) of the lower eyelids. The study will observe the effects of the topical agent over the course of 1 month following the initial treatment.

Start Date01 Oct 2008

Sponsor / Collaborator

TR Therapeutics, Inc.

100 Clinical Results associated with TR-987

Login to view more data

100 Translational Medicine associated with TR-987

Login to view more data

100 Patents (Medical) associated with TR-987

Login to view more data

100 Deals associated with TR-987

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic venous insufficiency	Phase 3	United States	TR Therapeutics, Inc.	28 Jan 2025
Varicose Ulcer	Phase 3	United States	TR Therapeutics, Inc.	28 Jan 2025
Wounds and Injuries	Phase 3	United States	TR Therapeutics, Inc.	28 Jan 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


WCD2023	Phase 2	Chronic venous insufficiency	82	TR987® 0.1% gel	polfeesoul(uunsgsxuvu) = iucgtdcbxm xfqawlfdzl (lexqfughor ) View more	Positive	03 Jul 2023
				Placebo gel	polfeesoul(uunsgsxuvu) = sbaagpwayx xfqawlfdzl (lexqfughor ) View more
NCT00656474 (CTgov)	Phase 1/2	Wounds and Injuries	12	GLYC-101 (GLYC-101 Active Retro-auricular Site (1 Per Participant))	tuxvwsctqv(prqereiqvd) = yccaiufbjb wmgjumjppp (uxqhxcsyrv, ykzxrkjfku - ltvfrixbzu) View more	-	25 Jul 2011
				Placebo (Placebo Retro-auricular Site (1 Per Participant))	tuxvwsctqv(prqereiqvd) = gwwoecebjs wmgjumjppp (uxqhxcsyrv, hhdexdexbf - hkqujxyzgh) View more